Achillion Reports 2014 Fourth Quarter and Year-End Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Data Could Lead to Achillion Pharmaceuticals (ACHN) Takeover By Year End - Analyst
March 6, 2015 1:32 PM ESTWilliam Blair analyst Y. Katherine Xu offered some interesting commentary on Achillion Pharmaceuticals (NASDAQ: ACHN) after the company's "uneventful" fourth quarter report. While keeping her Market Perform rating and lowering her price target to $14.00 (from $15.00), Xu highlighted that Achillion intends to initiate three different combination studies in the treatment of hepatitis C virus (HCV) during 2015 to... More
Achillion Pharma (ACHN) Misses Q4 EPS by 3c
March 5, 2015 6:08 AM ESTAchillion Pharma (NASDAQ: ACHN) reported Q4 EPS of ($0.21), $0.03 worse than the analyst estimate of ($0.18).
2015 Financial Guidance
At December 31, 2014, Achillion had cash, cash equivalents, marketable securities and interest and subscription receivables of approximately $159.2 million. Achillion completed a public offering of common stock on February 18, 2015, and... More
